title: Development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of epidermal growth factor receptor.
abstract: OBJECTIVE
  The aim of this study was the development of a knowledge assessment tool for dermatotoxicity caused by inhibitors of EGFR (intravenous regimens).
  
  
  METHODS
  Five nurses with experience in oncology created a 25-item questionnaire. The questionnaire was presented to six experts for assessment of face and content validity. Item analysis and reliability testing were evaluated on the test results of 76 nurses.
  
  
  RESULTS
  Face and content validity was achieved for 25 items. Two items with low biserial correlations were deleted. The values for item difficulty range from 0.2 to 0.7. The values for item discrimination ranged from 0.25 to 0.64. The complete post-tested 23-item questionnaire showed excellent internal consistency with Kuder-Richardson 20 score of 0.909. The Cohen κ tests showed that the questionnaire has very good test-retest reliability. The specific tool can be used in several studies, leading to the development of educational interventions.
authors.affiliation: Euroclinic Athens, Athens, Greece. dimpapa75@yahoo.gr
authors.forename: Dimitrios Konstantinos
authors.initials: DK
authors.lastname: Papageorgiou
authors.forename: Theocharis
authors.initials: T
authors.lastname: Konstantinidis
authors.forename: Theocharis
authors.initials: T
authors.lastname: Konsatntinidis
authors.forename: Nektaria
authors.initials: N
authors.lastname: Skandalaki
authors.forename: Anna
authors.initials: A
authors.lastname: Papadouri
authors.forename: Theodora
authors.initials: T
authors.lastname: Pappa
authors.forename: Stavroula
authors.initials: S
authors.lastname: Poulopoulou
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000068818:Cetuximab; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007262:Infusions, Intravenous; D009369:Neoplasms / Q000188:drug therapy* / Q000451:nursing*; D000077544:Panitumumab; D011788:Quality of Life; D015203:Reproducibility of Results; D011795:Surveys and Questionnaires
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000077544:Panitumumab; D066246:ErbB Receptors; D000068818:Cetuximab